use of tumor markers in testicular, prostate, colorectal, breast, and ...

References 77
542. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel
C, et al. uPM3, a new molecular urine test for the detection of
prostate cancer. Urology 2004;64:311–315.
543. Hessels D, Klein Gunnewiek JM, van OI, Karthaus HF, van
Leenders GJ, van BB, et al. DD3(PCA3)-based molecular urine
analysis for the diagnosis of prostate cancer. Eur Urol
2003;44:8–15.
544. Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin
MA. Prospective evaluation of AMACR (P504S) and basal cell
markers in the assessment of routine prostate needle biopsy
specimens. Hum Pathol 2004;35:1462–1468.
545. Jiang Z, Wu CL, Woda BA, Iczkowski KA, Chu PG, Tretiakova
MS, et al. Alpha-methylacyl-CoA racemase: a multi-institutional
study of a new prostate cancer marker. Histopathology
2004;45:218–225.
546. Kumar-Sinha C, Shah RB, Laxman B, Tomlins SA, Harwood J,
Schmitz W, et al. Elevated alpha-methylacyl-CoA racemase
enzymatic activity in prostate cancer. Am J Pathol 2004;
164:787–793.
547. Magi-Galluzzi C, Luo J, Isaacs WB, Hicks JL, de Marzo AM,
Epstein JI. Alpha-methylacyl-CoA racemase: a variably sensitive
immunohistochemical marker for the diagnosis of small
prostate cancer foci on needle biopsy. Am J Surg Pathol 2003;27:
1128–1133.
548. Rubin MA, Zerkowski MP, Camp RL, Kuefer R, Hofer MD,
Chinnaiyan AM, Rimm DL. Quantitative determination of
expression of the prostate cancer protein alpha-methylacyl-CoA
racemase using automated quantitative analysis (AQUA): a
novel paradigm for automated and continuous biomarker measurements.
Am J Pathol 2004;164:831–840.
549. Goessl C, Muller M, Heicappell R, Krause H, Straub B, Schrader
M, Miller K. DNA-based detection of prostate cancer in urine
after prostatic massage. Urology 2001;58:335–338.
550. Ntais C, Polycarpou A, Ioannidis JP. Association of GSTM1,
GSTT1, and GSTP1 gene polymorphisms with the risk of
prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers
Prev 2005;14:176–181.
551. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-
Muller S, Farinas AJ, et al. Aberrant promoter methylation profile
of prostate cancers and its relationship to clinicopathological
features. Clin Cancer Res 2002;8:514–519.
552. Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI,
Sidransky D. Optimal use of a panel of methylation markers
with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma.
Clin Cancer Res 2004;10:5518–5522.
553. Straub B, Muller M, Krause H, Goessl C, Schrader M,
Heicappell R, Miller K. Molecular staging of pelvic surgical
margins after radical prostatectomy: comparison of RT-PCR for
prostate-specific antigen and telomerase activity. Oncol Rep
2002;9:545–549.
554. Vicentini C, Gravina GL, Angelucci A, Pascale E, D’Ambrosio
E, Muzi P, et al. Detection of telomerase activity in prostate massage
samples improves differentiating prostate cancer from
benign prostatic hyperplasia. J Cancer Res Clin Oncol 2004;130:
217–221.
555. Ylikoski A, Pettersson K, Nurmi J, Irjala K, Karp M, Lilja H,
et al. Simultaneous quantification of prostate-specific antigen
and human glandular kallikrein 2 mRNA in blood samples from
patients with prostate cancer and benign disease. Clin Chem
2002;48:1265–1271.
556. Thomas GV, Horvath S, Smith BL, Crosby K, Lebel LA, Schrage
M, et al. Antibody-based profiling of the phosphoinositide 3-kinase
pathway in clinical prostate cancer. Clin Cancer Res
2004;10:8351–8356.
557. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Di CA, Xiao A,
et al. Pten dose dictates cancer progression in the prostate. PLoS
Biol 2003;1:E59.
558. Shaffer DR, Viale A, Ishiwata R, Leversha M, Olgac S, Manova
K, et al. Evidence for a p27 tumor suppressive function independent
of its role regulating cell proliferation in the prostate.
Proc Natl Acad Sci U S A 2005;102:210–215.
559. Gao H, Ouyang X, Banach-Petrosky W, Borowsky AD, Lin Y,
Kim M, et al. A critical role for p27kip1 gene dosage in a mouse
model of prostate carcinogenesis. Proc Natl Acad Sci U S A
2004;101:17204–17209.
560. Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond
ME, et al. Ki-67 staining is a strong predictor of distant metastasis
and mortality for men with prostate cancer treated with
radiotherapy plus androgen deprivation: Radiation Therapy
Oncology Group Trial 92-02. J Clin Oncol 2004;22:2133–2140.
561. Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM,
Anderl KL, et al. Loss of p53 and c-myc overrepresentation in
stage T(2-3)N(1-3)M(0) prostate cancer are potential markers
for cancer progression. Mod Pathol 2002;15:35–44.
562. Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas
GV, et al. Prostate stem cell antigen expression is associated
with gleason score, seminal vesicle invasion and capsular invasion
in prostate cancer. J Urol 2004;171:1117–1121.
563. Prostate Cancer Foundation: Report to the Nation on Prostate
Cancer. www.prostatecancerfoundation.org (Accessed May 27th,
2007).
564. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N,
Drake JC, et al. The role of thymidylate synthase expression in
prognosis and outcome of adjuvant chemotherapy in patients
with rectal cancer. J Clin Oncol 1994;12:2640–2647.
565. Boland CR. Clinical uses of microsatellite instability testing in
colorectal cancer: an ongoing challenge. J Clin Oncol 2007;25:
754–756.
566. Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark
N, Allegra CJ. Prognostic and predictive roles of high-degree
microsatellite instability in colon cancer: a National Cancer
Institute-National Surgical Adjuvant Breast and Bowel Project
Collaborative Study. J Clin Oncol 2007;25:767–772.
567. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N
Engl J Med 2003;348:919–932.
568. Rowley PT. Inherited susceptibility to colorectal cancer. Annu
Rev Med 2005;56:539–554.
569. Hendriks YM, de Jong AE, Morreau H, Tops CM, Vasen HF,
Wijnen JT, et al. Diagnostic approach and management of Lynch
syndrome (hereditary nonpolyposis colorectal carcinoma): a
guide for clinicians. CA Cancer J Clin 2006;56:213–225.
570. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder
E, Klapdor R, et al. Tumour markers in colorectal cancer:
European Group on Tumour Markers (EGTM) guidelines for
clinical use. Eur J Cancer 2007.
571. Van Cutsem EJDKW. ESMO minimum clinical recommendations
for diagnosis, adjuvant treatment and follow-up of primary
colon cancer. Ann Oncol 2005;16:i16–i17.
572. Tveit KM, Kataja VV. ESMO Minimum Clinical Recommendations
for diagnosis, treatment and follow-up of rectal cancer.
Ann Oncol 2005;16 Suppl 1:i20–21.
573. Van Cutsem EJ. Colon cancer: ESMO clinical recommendations
for diagnosis, adjuvant treatment of follow-up of primary colon
cancer. Ann Oncol 2007;18 (Suppl 2):ii21–22.